Study Raises Questions About Using 340B Claim Modifiers to Implement Medicare Drug Price Negotiation and Inflation Rebate Provisions

IQVIA white paper title page
IQVIA questions whether 340B claims identifiers can be used successfully to implement the Inflation Reduction Act's Medicare drug price negotiation and drug inflation rebate provisions.

New research by drug industry contractor IQVIA questions whether claims identifiers can be used successfully to exclude 340B-purchased drugs from new Medicare drug inflation rebates or to protect manufacturers from paying both a new negotiated Medicare price and a 340B

Read More »

America’s Essential Hospitals Asks HHS to Swiftly Repay 340B Hospitals for Unlawful Medicare Drug Payment Cuts

America's Essential Hospitals wordmark and tagline
America’s Essential Hospitals wants HHS “to swiftly remedy five years of unlawful drug reimbursement cuts to 340B hospitals under Medicare Part B.”

America’s Essential Hospitals asked U.S. Health and Human Services Secretary Xavier Becerra late last week “to swiftly remedy five years of unlawful drug reimbursement cuts to 340B
hospitals under Medicare Part B.”

“These cuts, and a delay in recompensing hospitals for

Read More »

J&J Announces Major Expansion of 340B Contract Pharmacy Limits; Pushback Is Likely

Johnson & Johnson signage in front of building
Johnson & Johnson is poised to become the first drug maker to place a condition on 340B sales and deliveries to covered entity in-house pharmacies.

Johnson & Johnson, the world’s biggest drug company, yesterday announced a major expansion of the drug industry’s campaign to set limits on 340B drug sales.

On March 7, it is poised to become the first drug maker to place a

Read More »

Connecticut’s Democratic Governor Wants Hospitals to Report 340B Earnings and Manufacturers to Resume 340B Pricing

A Connecticut state health agency under Gov. Ned Lamont (D) proposed legislation to implement certain 340B provider reporting requirements.

Connecticut’s Democratic governor wants his state’s 340B hospitals to start filing annual reports disclosing their 340B drug revenues and summarizing how they use the money to benefit their communities. Health centers and other 340B grantee covered entities would be exempt

Read More »

Baldwin, a 340B Entity Ally, Will Chair Senate Health Appropriations Subcommittee

Sen. Tammy Baldwin (D-WI)
U.S. Sen. Tammy Baldwin (D-Wis.) is the new chair of the Senate Labor, Health and Human Services, Education, and Related Agencies Appropriations Subcommittee.

U.S. Sen. Tammy Baldwin (D-Wis.), who has a long track record of support for 340B covered entities, is the new leader of a Senate Appropriations subcommittee with influence over 340B policy.

Baldwin announced yesterday she will serve as chair

Read More »

340B Pricing May Be Coming to Contrast Agents, Radiopharmaceuticals, and OTC Monograph Drugs

Contrast media image of kidneys
Providers may get previously unavailable access to 340B pricing on contrast agents, radiopharmaceuticals, and OTC monograph drugs thanks to language in a a federal FY 2023 spending law.

Health care providers in the coming months may get previously unavailable access to 340B pricing on contrast agents, radiopharmaceuticals, and so-called “OTC monograph” drugs thanks to language tucked into the massive fiscal year 2023 federal spending bill signed into law

Read More »

Ex-CMS Leader Verma: Big Health Systems Use 340B to Expand Profit and Monopoly Power

CMS Administrator Seema Verma speaks at White House podium
Health systems use 340B to expand "their profit and monopoly power," Trump administration CMS Administrator Seema Verma said in a Wall Street Journal op-ed.

Seema Verma, ex-President Trump’s Centers for Medicare & Medicaid Services administrator, said in a Wall Street Journal op-ed yesterday that large health systems work to expand their use of the 340B program “and thus their profit and monopoly power.”

“Across

Read More »

CMS Seeks Input on Excluding 340B Drugs from New Medicare Part D Inflation Rebates

Part D inflation rebate press release
CMS is seeking comment on how best to exclude 340B drugs from new Part D inflation rebate invoices.

The U.S. Centers for Medicare & Medicaid Services is seeking comments by March 11 on “the most reliable way to identify” 340B-purchased drugs dispensed to Medicare Part D beneficiaries so they can be excluded from new Part D inflation rebate

Read More »

Sanders, Asked About Abuse in 340B, Cites His Past Effort to End a Hospital’s Tax Exemption

Sen. Bernie Sanders speaking at a podium
Senate HELP chair Bernie Sanders (I-Vt.) talked about taking away hospitals' tax-exempt status when he was asked during an interview about alleged hospital abuse of 340B.

U.S. Sen. Bernie Sanders (I-Vt.), the new chair of the Senate committee that oversees the 340B program, recently answered a reporter’s question about alleged hospital abuse of 340B by noting that he tried to revoke a Burlington, Vt., hospital’s tax-exempt

Read More »

More Entities Might Share 340B Contract Pharmacy Claims Data if the Process Improves and Actually Restores 340B Pricing, Survey Shows

laptop screen depicting data upload
More 340B entities would share contract pharmacy claims data with manufacturers if the process was better and got 340B pricing turned back on reliably, a survey by McKesson found.

While most 340B covered entities do not share their contract pharmacy claims data with drug makers to restore access to 340B pricing, many would do so if the process was better and got 340B pricing turned back on reliably, a

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live